Clearmind Medicine Inc. Common Shares (CMND)
$1.16
$-0.54
(-31.76%)
As on 04-Sep-2026 16:28EDT
Market cap
$2 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.8
-
Debt to Equity
0
-
Book Value
$11.3
-
EPS
$--
-
Face value
--
-
Shares outstanding
1,485,551
10 Years Aggregate
CFO
$-14.74 Mln
EBITDA
$-20.89 Mln
Net Profit
$-25.80 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Clearmind Medicine Inc. Common Shares (CMND)
| -93.6 | -28.8 | -60.1 | -99.7 | -93.8 | -91.5 | -- |
|
BSE Sensex*
| -10.3 | -3.8 | 2.4 | -5.8 | 4.9 | 5.4 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Clearmind Medicine Inc. Common Shares (CMND)
| -96.7 | -50.6 | -97.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Clearmind Medicine Inc. Common Shares (CMND)
|
1.2 | 1.7 | 0.0 | -7.9 | -- | -120.1 | -- | 0.2 |
| 1.8 | 14.5 | 7.6 | -3.8 | -73.9 | -39.4 | -- | 1.1 | |
| 17.3 | 2,249.1 | 120.8 | -57.8 | -42.6 | -9.9 | -- | 3.9 |
Shareholding Pattern
View DetailsAbout Clearmind Medicine Inc. Common Shares (CMND)
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as... weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada. Read more
-
Chief Executive Officer
Dr. Adi Zuloff-Shani Ph.D.
-
Chief Executive Officer
Dr. Adi Zuloff-Shani Ph.D.
-
Headquarters
Vancouver, BC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Clearmind Medicine Inc. Common Shares (CMND)
What is the current share price of Clearmind Medicine Inc Common Shares (CMND) Today?
The share price of Clearmind Medicine Inc Common Shares (CMND) is $1.16 (NASDAQ) as of 04-Sep-2026 16:28 EDT. Clearmind Medicine Inc Common Shares (CMND) has given a return of -93.79% in the last 3 years.
What is the current PB & PE ratio of Clearmind Medicine Inc Common Shares (CMND)?
Since, TTM earnings of Clearmind Medicine Inc Common Shares (CMND) is negative, P/E ratio is not available.
The P/B ratio of Clearmind Medicine Inc Common Shares (CMND) is 0.23 times as on 04-Sep-2026, a 95 discount to its peers’ median range of 4.90 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-- |
-- |
2024 |
-- |
-- |
2023 |
-- |
-- |
2023 |
-- |
-- |
2022 |
-- |
-- |
What is the 52 Week High and Low of Clearmind Medicine Inc Common Shares (CMND)?
The 52-week high and low of Clearmind Medicine Inc Common Shares (CMND) are Rs 524.00 and Rs 1.16 as of 07-Sep-2026.
What is the market cap of Clearmind Medicine Inc Common Shares (CMND)?
Clearmind Medicine Inc Common Shares (CMND) has a market capitalisation of $ 2 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Clearmind Medicine Inc Common Shares (CMND)?
Before investing in Clearmind Medicine Inc Common Shares (CMND), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.